Boothbay Fund Management, LLC Immunovant, Inc. Call Options Transaction History

Boothbay Fund Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $3.4 Million - $3.4 Million	123,700 Added 466.79%	150,200 $4.13 Million
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $665,150 - $837,665	26,500 New	26,500 $699,000
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $2.36 Million - $3.33 Million	-75,300 Reduced 51.29%	71,500 $3.01 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $1.5 Million - $3.23 Million	80,900 Added 122.76%	146,800 $5.64 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $479,960 - $802,750	33,800 Added 105.3%	65,900 $1.25 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $490,167 - $633,012	32,100 New	32,100 $497,000
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $425,820 - $763,305	45,300 New	45,300 $479,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.